Cardiovascular risk assessment is becoming increasingly important in an era of personalised therapy. In this short podcast, Professor Steve Nissen – in conversation with Professor Stephen Nicholls and Professor Sophia Zoungas – explains what is needed to advance the concept of polygenic risk and make it clinically-useful. They also discuss how incentives could bolster the ...
Unanswered questions in cardiovascular risk assessment
27 May 2020
Sponsored by Amgen Australia Pty Ltd